Karyopharm Therapeutics Inc. (NASDAQ:KPTI) Q4 2023 Earnings Call Transcript

Unidentified Analyst: Thank you so much.

Richard Paulson: Thanks Joe.

Operator: And your next question comes from the line of Steve Bersey from H.C. Wainwright. Your line is open.

Steve Bersey: Hi. This is Steve on for Ed. So you’re referring there is a shift — more of a shift into earlier lines of therapy and increased duration of patient on drug. Can you put any numbers to that? And is there a difference between second line to fourth line and penta-refractory patients?

Richard Paulson: Yeah. Thanks Steve and I will just add a high-level data that looking at the numbers in detail is very difficult and it’s more directional. And I’ll turn to Sohanya you talked about that impact as we’re looking at the ongoing shift into the earlier lines which again is right in line with our strategy and where we’re going to continue to focus. Sohanya?

Sohanya Cheng: Yeah. So we continue to see an upward trend in our duration of therapy and that is really primarily driven by the earlier line patients. So do tend to stay on therapy much longer than the later line patients. And we are also seeing that duration increase, because our physicians are getting more comfortable in managing these patients with the right supportive care at the lower dose and so on. So again, I won’t disclose the specifics of the duration, but we see an upward trend. And we expect to continue to see a positive shift in our duration, as we move forward.

Steve Bersey: Okay. Thanks for taking our question.

Richard Paulson: Thanks Steve.

Operator: Thank you. Our Q&A session has now ended. I would like to turn it back to Richard Paulson, President and Chief Executive Officer of Karyopharm for closing comments.

Richard Paulson: Thank you, Ludy. And once again thank you everyone for joining us today. And I think as I mentioned before, we’re very excited about our innovation and growth strategy. Our Phase 3 clinical trials are moving forward rapidly. And we believe, the largest opportunities for selinexor are yet to come, as we focus on delivering this next phase of growth. And as we mentioned, everybody inside Karyopharm is focused on striving each day for patients high unmet needs and working to generate value for our patients and shareholders. So once again thank you for joining us today.

Operator: Thank you. And ladies and gentlemen, this concludes today’s conference call. Thank you for participating. You may now disconnect.